Savara (NASDAQ: SVRA)
Savara Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Savara Company Info
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.
News & Analysis
Why Shares of Savara Jumped on Tuesday
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
Why Shares of Savara Soared This Week
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
Why HEXO, Savara, and Cooper-Standard Holdings Slumped Today
A host of factors pulled some stocks down.
Here's Why Savara Pharmaceuticals Collapsed Today
Investors just received some bad news about the company's lead drug candidate.
Why Synaptics, iQiyi, and Savara Jumped Today
Find out which of these stocks posted the biggest gain.
Why Savara Inc. Is Soaring Today
Traders cheer after the company receives positive analyst coverage. Here's what investors need to know.
Valuation
Earnings Transcripts
Savara Inc. (SVRA) Q1 2019 Earnings Call Transcript
SVRA earnings call for the period ending March 31, 2019.
Savara Inc. (SVRA) Q4 2018 Earnings Conference Call Transcript
SVRA earnings call for the period ending December 31, 2018.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.